

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Medlive Technology Co., Ltd.

醫脈通科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2192)

VOLUNTARY ANNOUNCEMENT

BECOMING A CONSTITUENT OF HANG SENG COMPOSITE INDEX

This announcement is made by Medlive Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide shareholders of the Company and potential investors on the Group’s latest development.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company has been selected as a constituent stock of the Hang Seng Composite Index (“**HSCI**”) by Hang Seng Indexes Company Limited, with effect from 6 December 2021. The HSCI offers a comprehensive Hong Kong market benchmark that covers about 95% of the total market capitalization of companies listed on the Main Board of The Stock Exchange of Hong Kong Limited.

The Board is of the view that the inclusion of the Company into the HSCI reflects the capital market’s recognition of the Group’s positive business performance and growth outlook and is expected such inclusion will expand the shareholder base and increase trading liquidity of the shares of the Company, resulting in enhanced value of investment and reputation of the Company in the capital market.

The Board would like to thank its shareholders and investors for their support. The Company strives to make use of its competitive advantage to develop its business and create value for its shareholders.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Medlive Technology Co., Ltd.
Tian Liping

Chairwoman and Chief Executive Officer

Hong Kong, 22 November 2021

As of the date of this announcement, the Board comprises Ms. Tian Liping, Mr. Tian Lixin, Mr. Tian Lijun and Ms. Zhou Xin as executive Directors; Mr. Eiji Tsuchiya and Dr. Li Zhuolin as non-executive Directors; and Mr. Richard Yeh, Dr. Ma Jun and Ms. Wang Shan as independent non-executive Directors.